紫杉醇联合卡铂治疗晚期非小细胞肺癌的临床观察  

Clinic observation of treating advanced stage of NSCLC with paclitaxel and carboplatin

作　　者：廖开莲[1] 杨敬儒[1] 欧阳周[1] 肖华伍[1] 

机构地区：[1]湖南省肿瘤医院内四科,湖南长沙410006

出　　处：《世界肿瘤杂志》2006年第3期205-206,共2页Tumour Journal of the World

摘　　要：目的评价紫杉醇联合卡铂化疗对晚期非小细胞肺癌（NSCLC）病人的疗效和毒副作用。方法紫杉醇每次剂量135mg／m^2，3h内静脉滴注，d1给药。在紫杉醇化疗前给予地塞米松，笨海拉明和西咪替丁预防过敏反应。卡铂每次剂量300mg／m^2，1h内静脉滴注，d1给药，3wk一个周期。结果总有效率为46．9％，初治者21例，有效率52.4％，复治者11例，有效率36．4％，中位生存期6．5mo。毒性反应主要为脱发、骨髓抑制、消化道反应及肌肉疼痛、周围神经毒性、肝功能异常、皮疹为轻度反应。结论紫杉醇加卡铂是治疗晚期NSCLC有效的联合化疗方案，其毒性反应容易耐受，对既往化疗应用过顺铂，恶心、呕吐〈Ⅲ度病人，是比较理想的方案之一。Objective To evaluate the efficacy and toxicity of Paclitaxel and carbo-platin in treatment of advanced stage of NSCLC. Methods Paclitaxel, 135mg/m^2 iv gtt for 3 hrs, dl; anti-allergic drugs were applied before the usage of Paclitaxel. Carboplatin, iv gtt for lhr, 300mg/m^2, dl, cycle was repeated every 3 wks. Results Overall efficacy reached 46.9%; 52.4%among initial treated patients and 36.4% among retreatment patients. MST reached 6.5mo. Common toxicity included alopecia, bone marrow depression, gastrointestinal tract reaction, peripheral nerve toxicity, abnormality of liver function and skin rash, which were all mild degree. Conclusions Combined regimen including paclitaxel and carboplatin is effective and well tolerated in treating advanced stage of NSCLC. It is an alternative regimen for retreatment patients once experienced vomiting over grade Ⅲ while received cisplatin.

关 键 词：非小细胞肺癌 紫杉醇 卡铂 化疗 

分 类 号：R734.2[医药卫生—肿瘤]